{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Coulson AB"],"funding":["Cancer Research UK","Takeda","Medical Research Council","Bristol Myers Squibb Company"],"pagination":["e056147"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9163533"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(6)"],"pubmed_abstract":["Introduction
Multiple myeloma is a bone marrow cancer, which predominantly affects older people. The incidence is increasing in an ageing population.Over the last 10 years, patient outcomes have improved. However, this is less apparent in older, less fit patients, who are ineligible for stem cell transplant. Research is required in this patient group, taking into account frailty and aiming to improve: treatment tolerability, clinical outcomes and quality of life.Methods and analysis
Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma is a national, phase III, multicentre, randomised controlled trial comparing standard (reactive) and frailty-adjusted (adaptive) induction therapy delivery with ixazomib, lenalidomide and dexametha"],"journal":["BMJ open"],"pubmed_title":["<i>F</i>railty-adjusted therapy <i>i</i>n <i>T</i>ransplant <i>N</i>on-<i>E</i>ligible patient<i>s</i> with newly diagno<i>s</i>ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial."],"pmcid":["PMC9163533"],"funding_grant_id":["C7852/A25447","Not applicable","C37712/A21282","21282","25447","29957","MR/W030128/1"],"pubmed_authors":["Meads D","Cairns DA","Pawlyn C","Henderson R","Kishore B","Olivier C","Best P","Hockaday A","de Tute R","Boyd K","Jackson G","Rabin N","Bird J","Kaiser M","Royle KL","Gardner H","Owen R","Coulson AB","Dawkins B","Jenner M","Drayson M","Cook G","Parrish C","Jones J","Bowcock S"],"additional_accession":[]},"is_claimable":false,"name":"<i>F</i>railty-adjusted therapy <i>i</i>n <i>T</i>ransplant <i>N</i>on-<i>E</i>ligible patient<i>s</i> with newly diagno<i>s</i>ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial.","description":"Introduction
Multiple myeloma is a bone marrow cancer, which predominantly affects older people. The incidence is increasing in an ageing population.Over the last 10 years, patient outcomes have improved. However, this is less apparent in older, less fit patients, who are ineligible for stem cell transplant. Research is required in this patient group, taking into account frailty and aiming to improve: treatment tolerability, clinical outcomes and quality of life.Methods and analysis
Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma is a national, phase III, multicentre, randomised controlled trial comparing standard (reactive) and frailty-adjusted (adaptive) induction therapy delivery with ixazomib, lenalidomide and dexametha","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2026-05-10T01:41:48.018Z","creation":"2025-02-19T02:57:37.826Z"},"accession":"S-EPMC9163533","cross_references":{"pubmed":["35654466"],"doi":["10.1136/bmjopen-2021-056147"]}}